MTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis

Pharmacological Research

Volumn 107, Issue , 2016, Pages 333-343

  Citraro, Rita ^a   Leo, Antonio ^a   Constanti, Andrew ^b   Russo, Emilio ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Animal epilepsy models; Epilepsy; Epileptogenesis; mTOR; mTOR inhibitors; Tuberous sclerosis complex

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TEMSIROLIMUS; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CORTICAL DYSPLASIA; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPILEPSY; EPILEPTOGENESIS; HUMAN; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TEMPORAL LOBE EPILEPSY; TUBEROUS SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; EPILEPSY; HUMANS; TOR SERINE-THREONINE KINASES;

EID: 84962791864     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.03.039     Document Type: Review

References (151)

1. P. Kwan, and M.J. Brodie Refractory epilepsy: mechanisms and solutions Expert Rev. Neurother. 6 2006 397 406
2. C. Palleria, A. Coppola, R. Citraro, L. Del Gaudio, S. Striano, G. De Sarro, and E. Russo Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis Expert Opin. Pharmacother. 16 2015 2355 2371
3. H. Potschka, and M.J. Brodie Pharmacoresistance Handbook Clin. Neurol. 108 2012 741 757
4. A. Pitkanen, and J. Engel Jr. Past and present definitions of epileptogenesis and its biomarkers Neurotherapeutics 11 2014 231 241
5. H.S. White, and W. Loscher Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies Neurotherapeutics 11 2014 373 384
6. E. Trinka, and F. Brigo Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward Curr. Opin. Neurol. 27 2014 227 235
7. N. Takei, and H. Nawa Mtor signaling and its roles in normal and abnormal brain development Front. Mol. Neurosci. 7 2014 28
8. J. Bockaert, and P. Marin Mtor in brain physiology and pathologies Physiol. Rev. 95 2015 1157 1187
9. A.P. Ostendorf, and M. Wong Mtor inhibition in epilepsy: rationale and clinical perspectives CNS Drugs 29 2015 91 99
10. J. Liu, C. Reeves, Z. Michalak, A. Coppola, B. Diehl, S.M. Sisodiya, and M. Thom Evidence for mtor pathway activation in a spectrum of epilepsy-associated pathologies Acta Neuropathol. Commun. 2 2014 71
11. E. Russo, R. Citraro, A. Constanti, and G. De Sarro The mtor signaling pathway in the brain: focus on epilepsy and epileptogenesis Mol. Neurobiol. 46 2012 662 681
12. M. Wong Mammalian target of rapamycin (mtor) pathways in neurological diseases Biomed. J. 36 2013 40 50
13. P.B. Crino Mtor: a pathogenic signaling pathway in developmental brain malformations Trends Mol. Med. 17 2011 734 742
14. P.B. Crino Mtor signaling in epilepsy: insights from malformations of cortical development Cold Spring Harbor Perspect. Med. 5 2015
15. P. Curatolo, and R. Moavero Mtor inhibitors as a new therapeutic option for epilepsy Expert Rev. Neurother. 13 2013 627 638
16. K. Sadowski, K. Kotulska-Jozwiak, and S. Jozwiak Role of mtor inhibitors in epilepsy treatment Pharmacol. Rep. 67 2015 636 646
17. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, R. Kuperman, O. Witt, M.H. Kohrman, J.R. Flamini, J.Y. Wu, P. Curatolo, P.J. de Vries, V.H. Whittemore, E.A. Thiele, J.P. Ford, G. Shah, H. Cauwel, D. Lebwohl, T. Sahmoud, and S. Jozwiak Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): A multicentre randomised, placebo-controlled phase 3 trial Lancet 381 2013 125 132
18. M. Perek-Polnik, S. Jozwiak, E. Jurkiewicz, D. Perek, and K. Kotulska Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex Eur. J. Paediatr. Neurol. 16 2012 83 85
19. M. Wong Mammalian target of rapamycin (mtor) activation in focal cortical dysplasia and related focal cortical malformations Exp. Neurol. 244 2013 22 26
20. L.H. Zeng, N.R. Rensing, and M. Wong The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy J. Neurosci. 29 2009 6964 6972
21. P.S. Buckmaster, and F.H. Lew Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy J. Neurosci. 31 2011 2337 2347
22. A. Sliwa, G. Plucinska, J. Bednarczyk, and K. Lukasiuk Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy Neurosci. Lett. 509 2012 105 109
23. R. Zoncu, A. Efeyan, and D.M. Sabatini Mtor: from growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 12 2011 21 35
24. C.K. Tsang, H. Qi, L.F. Liu, and X.F. Zheng Targeting mammalian target of rapamycin (mtor) for health and diseases Drug Discov. Today 12 2007 112 124
25. Z.Z. Chong, Q. Yao, and H.H. Li The rationale of targeting mammalian target of rapamycin for ischemic stroke Cell. Signalling 25 2013 1598 1607
26. D.K. Sandsmark, C. Pelletier, J.D. Weber, and D.H. Gutmann Mammalian target of rapamycin: master regulator of cell growth in the nervous system Histol Histopathol. 22 2007 895 903
27. C. Dello Russo, L. Lisi, D.L. Feinstein, and P. Navarra Mtor kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis Glia 61 2013 301 311
28. J. Jaworski, S. Spangler, D.P. Seeburg, C.C. Hoogenraad, and M. Sheng Control of dendritic arborization by the phosphoinositide-3'-kinase-akt-mammalian target of rapamycin pathway J. Neurosci. 25 2005 11300 11312
29. V. Kumar, M.X. Zhang, M.W. Swank, J. Kunz, and G.Y. Wu Regulation of dendritic morphogenesis by ras-pi3k-akt-mtor and ras-mapk signaling pathways J. Neurosci. 25 2005 11288 11299
30. Y. Lee da Roles of mtor signaling in brain development Exp. Neurobiol. 24 2015 177 185
31. R.Y. Pun, I.J. Rolle, C.L. Lasarge, B.E. Hosford, J.M. Rosen, J.D. Uhl, S.N. Schmeltzer, C. Faulkner, S.L. Bronson, B.L. Murphy, D.A. Richards, K.D. Holland, and S.C. Danzer Excessive activation of mtor in postnatally generated granule cells is sufficient to cause epilepsy Neuron 75 2012 1022 1034
32. X. Huang, J. McMahon, J. Yang, D. Shin, and Y. Huang Rapamycin down-regulates kcc2 expression and increases seizure susceptibility to convulsants in immature rats Neuroscience 219 2012 33 47
33. K.F. Raab-Graham, P.C. Haddick, Y.N. Jan, and L.Y. Jan Activity- and mtor-dependent suppression of kv1.1 channel mrna translation in dendrites Science 314 2006 144 148
34. M. Wong, K.C. Ess, E.J. Uhlmann, L.A. Jansen, W. Li, P.B. Crino, S. Mennerick, K.A. Yamada, and D.H. Gutmann Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model Ann. Neurol. 54 2003 251 256
35. N. Lozovaya, S. Gataullina, T. Tsintsadze, V. Tsintsadze, E. Pallesi-Pocachard, M. Minlebaev, N.A. Goriounova, E. Buhler, F. Watrin, S. Shityakov, A.J. Becker, A. Bordey, M. Milh, D. Scavarda, C. Bulteau, G. Dorfmuller, O. Delalande, A. Represa, C. Cardoso, O. Dulac, Y. Ben-Ari, and N. Burnashev Selective suppression of excessive glun2c expression rescues early epilepsy in a tuberous sclerosis murine model Nat. Commun. 5 2014 4563
36. K. Maiese Targeting molecules to medicine with mtor, autophagy, and neurodegenerative disorders Br. J. Clin. Pharmacol. 2015
37. M. Costa-Mattioli, and L.M. Monteggia Mtor complexes in neurodevelopmental and neuropsychiatric disorders Nat. Neurosci. 16 2013 1537 1543
38. H.M. Abelaira, G.Z. Reus, M.V. Neotti, and J. Quevedo The role of mtor in depression and antidepressant responses Life Sci. 101 2014 10 14
39. C.S. Jernigan, D.B. Goswami, M.C. Austin, A.H. Iyo, A. Chandran, C.A. Stockmeier, and B. Karolewicz The mtor signaling pathway in the prefrontal cortex is compromised in major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1774 1779
40. A. Chandran, A.H. Iyo, C.S. Jernigan, B. Legutko, M.C. Austin, and B. Karolewicz Reduced phosphorylation of the mtor signaling pathway components in the amygdala of rats exposed to chronic stress Prog. Neuropsychopharmacol. Biol. Psychiatry 40 2013 240 245
41. K.R. Howell, A. Kutiyanawalla, and A. Pillai Long-term continuous corticosterone treatment decreases vegf receptor-2 expression in frontal cortex PLoS One 6 2011 e20198
42. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman Mtor-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists Science 329 2010 959 964
43. C. Yang, J. Shen, T. Hong, T.T. Hu, Z.J. Li, H.T. Zhang, Y.J. Zhang, Z.Q. Zhou, and J.J. Yang Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex Mol. Med. Rep. 8 2013 887 890
44. A. Sharma, C.A. Hoeffer, Y. Takayasu, T. Miyawaki, S.M. McBride, E. Klann, and R.S. Zukin Dysregulation of mtor signaling in fragile x syndrome J. Neurosci. 30 2010 694 702
45. A.M. Iyer, J. van Scheppingen, I. Milenkovic, J.J. Anink, H. Adle-Biassette, G.G. Kovacs, and E. Aronica Mtor hyperactivation in down syndrome hippocampus appears early during development J. Neuropathol. Exp. Neurol. 73 2014 671 683
46. S. Ricciardi, E.M. Boggio, S. Grosso, G. Lonetti, G. Forlani, G. Stefanelli, E. Calcagno, N. Morello, N. Landsberger, S. Biffo, T. Pizzorusso, M. Giustetto, and V. Broccoli Reduced akt/mtor signaling and protein synthesis dysregulation in a rett syndrome animal model Hum. Mol. Genet. 20 2011 1182 1196
47. T.E. Graber, P.K. McCamphill, and W.S. Sossin A recollection of mtor signaling in learning and memory Learn. Mem. 20 2013 518 530
48. C.A. Hoeffer, and E. Klann Mtor signaling: at the crossroads of plasticity, memory and disease Trends Neurosci. 33 2010 67 75
49. M. Dierssen, and G.J. Ramakers Dendritic pathology in mental retardation: from molecular genetics to neurobiology Genes Brain Behav. 5 Suppl. 2 2006 48 60
50. R.G. Parsons, G.M. Gafford, and F.J. Helmstetter Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons J. Neurosci. 26 2006 12977 12983
51. L. Stoica, P.J. Zhu, W. Huang, H. Zhou, S.C. Kozma, and M. Costa-Mattioli Selective pharmacogenetic inhibition of mammalian target of rapamycin complex i (mtorc1) blocks long-term synaptic plasticity and memory storage Proc. Natl. Acad. Sci. U. S. A. 108 2011 3791 3796
52. P.K. Dash, S.A. Orsi, and A.N. Moore Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-mammalian target of rapamycin pathway J. Neurosci. 26 2006 8048 8056
53. C.A. Hoeffer, W. Tang, H. Wong, A. Santillan, R.J. Patterson, L.A. Martinez, M.V. Tejada-Simon, R. Paylor, S.L. Hamilton, and E. Klann Removal of fkbp12 enhances mtor-raptor interactions, ltp, memory, and perseverative/repetitive behavior Neuron 60 2008 832 845
54. W. Tischmeyer, H. Schicknick, M. Kraus, C.I. Seidenbecher, S. Staak, H. Scheich, and E.D. Gundelfinger Rapamycin-sensitive signalling in long-term consolidation of auditory cortex-dependent memory Eur. J. Neurosci. 18 2003 942 950
55. D. Ehninger, P.J. de Vries, and A.J. Silva From mtor to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis J. Intellect. Disabil. Res. 53 2009 838 851
56. D. Ehninger, S. Han, C. Shilyansky, Y. Zhou, W. Li, D.J. Kwiatkowski, V. Ramesh, and A.J. Silva Reversal of learning deficits in a tsc2+/- mouse model of tuberous sclerosis Nat. Med. 14 2008 843 848
57. J.O. Lipton, and M. Sahin The neurology of mtor Neuron 84 2014 275 291
58. Z.M. Ignacio, G.Z. Reus, C.O. Arent, H.M. Abelaira, M.R. Pitcher, and J. Quevedo New perspectives on the involvement of mtor in depression as well as in the action of antidepressant drugs Br. J. Clin. Pharmacol. 2015
59. B. Nyfeler, P. Bergman, C.J. Wilson, and L.O. Murphy Quantitative visualization of autophagy induction by mtor inhibitors Methods Mol. Biol. 821 2012 239 250
60. M. Arrasate, and S. Finkbeiner Protein aggregates in huntington's disease Exp. Neurol. 238 2012 1 11
61. G.B. Irvine, O.M. El-Agnaf, G.M. Shankar, and D.M. Walsh Protein aggregation in the brain: the molecular basis for alzheimer's and parkinson's diseases Mol. Med. 14 2008 451 464
62. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, F. Scaravilli, D.F. Easton, R. Duden, C.J. O'Kane, and D.C. Rubinsztein Inhibition of mtor induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of huntington disease Nat. Genet. 36 2004 585 595
63. Z. Berger, B. Ravikumar, F.M. Menzies, L.G. Oroz, B.R. Underwood, M.N. Pangalos, I. Schmitt, U. Wullner, B.O. Evert, C.J. O'Kane, and D.C. Rubinsztein Rapamycin alleviates toxicity of different aggregate-prone proteins Hum. Mol. Genet. 15 2006 433 442
64. X.F. Meng, J.T. Yu, J.H. Song, S. Chi, and L. Tan Role of the mtor signaling pathway in epilepsy J. Neurol. Sci. 332 2013 4 15
65. S.S. McDaniel, and M. Wong Therapeutic role of mammalian target of rapamycin (mtor) inhibition in preventing epileptogenesis Neurosci. Lett. 497 2011 231 239
66. M. Wong, and P.B. Crino Mtor and epileptogenesis in developmental brain malformations J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, Jasper's Basic Mechanisms of the Epilepsies 2012 Delgado-Escueta AV, eds. Bethesda (MD)
67. C.L. Lasarge, and S.C. Danzer Mechanisms regulating neuronal excitability and seizure development following mtor pathway hyperactivation Front. Mol. Neurosci. 7 2014 18
68. A.S. Galanopoulou, J.A. Gorter, and C. Cepeda Finding a better drug for epilepsy: the mtor pathway as an antiepileptogenic target Epilepsia 53 2012 1119 1130
69. S. Erlich, A. Alexandrovich, E. Shohami, and R. Pinkas-Kramarski Rapamycin is a neuroprotective treatment for traumatic brain injury Neurobiol. Dis. 26 2007 86 93
70. E. Raffo, A. Coppola, T. Ono, S.W. Briggs, and A.S. Galanopoulou A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol. Dis. 43 2011 322 329
71. S. Carloni, S. Girelli, C. Scopa, G. Buonocore, M. Longini, and W. Balduini Activation of autophagy and akt/creb signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia Autophagy 6 2010 366 377
72. G.L. Holmes, and C.E. Stafstrom Tuberous sclerosis complex and epilepsy: recent developments and future challenges Epilepsia 48 2007 617 630
73. P. Curatolo, and B.L. Maria Tuberous sclerosis Handbook Clin. Neurol. 111 2013 323 331
74. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, P. Mangeshkar, K.A. Wilson, A. Byars, T. Sahmoud, and D.N. Franz Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N. Engl. J. Med. 363 2010 1801 1811
75. P. Curatolo Mechanistic target of rapamycin (mtor) in tuberous sclerosis complex-associated epilepsy Pediatr. Neurol. 52 2015 281 289
76. D.A. Krueger Management of cns-related disease manifestations in patients with tuberous sclerosis complex Curr. Treat. Options Neurol. 15 2013 618 633
77. M. Wong Mammalian target of rapamycin (mtor) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies Epilepsia 51 2010 27 36
78. L. Meikle, D.M. Talos, H. Onda, K. Pollizzi, A. Rotenberg, M. Sahin, F.E. Jensen, and D.J. Kwiatkowski A mouse model of tuberous sclerosis: neuronal loss of tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival J. Neurosci. 27 2007 5546 5558
79. D.M. Feliciano, T. Su, J. Lopez, J.C. Platel, and A. Bordey Single-cell tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice J. Clin. Invest. 121 2011 1596 1607
80. D.M. Feliciano, T.V. Lin, N.W. Hartman, C.M. Bartley, C. Kubera, L. Hsieh, C. Lafourcade, R.A. O'Keefe, and A. Bordey A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits Int. J. Dev. Neurosci. 31 2013 667 678
81. M. Wong A tuber-ful animal model of tuberous sclerosis at last? Epilepsy Curr. 1 2012
82. E.J. Uhlmann, W. Li, D.K. Scheidenhelm, C.L. Gau, F. Tamanoi, and D.H. Gutmann Loss of tuberous sclerosis complex 1 (tsc1) expression results in increased rheb/s6k pathway signaling important for astrocyte cell size regulation Glia 47 2004 180 188
83. J.P. MacKeigan, and D.A. Krueger Differentiating the mtor inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex Neuro Oncol. 17 2015 1550 1559
84. K. Sadowski, K. Kotulska, R.A. Schwartz, and S. Jozwiak Systemic effects of treatment with mtor inhibitors in tuberous sclerosis complex: a comprehensive review J. Eur. Acad. Dermatol. Venereol. 2015
85. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann. Neurol. 63 2008 444 453
86. L. Meikle, K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, M. Sahin, and D.J. Kwiatkowski Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mtor) inhibitors: effects on mtorc1 and akt signaling lead to improved survival and function J. Neurosci. 28 2008 5422 5432
87. J. Goto, D.M. Talos, P. Klein, W. Qin, Y.I. Chekaluk, S. Anderl, I.A. Malinowska, A. Di Nardo, R.T. Bronson, J.A. Chan, H.V. Vinters, S.G. Kernie, F.E. Jensen, M. Sahin, and D.J. Kwiatkowski Regulable neural progenitor-specific tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex Proc. Natl. Acad. Sci. U. S. A. 108 2011 E1070 1079
88. L.H. Zeng, N.R. Rensing, B. Zhang, D.H. Gutmann, M.J. Gambello, and M. Wong Tsc2 gene inactivation causes a more severe epilepsy phenotype than tsc1 inactivation in a mouse model of tuberous sclerosis complex Hum. Mol. Genet. 20 2011 445 454
89. B. Zhang, J. Zou, N.R. Rensing, M. Yang, and M. Wong Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex Neurobiol. Dis. 80 2015 70 79
90. E. Abs, S.M. Goorden, J. Schreiber, I.E. Overwater, M. Hoogeveen-Westerveld, C.F. Bruinsma, E. Aganovic, N.Z. Borgesius, M. Nellist, and Y. Elgersma Torc1-dependent epilepsy caused by acute biallelic tsc1 deletion in adult mice Ann. Neurol. 74 2013 569 579
91. D. Friedman, M. Bogner, K. Parker-Menzer, and O. Devinsky Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex Epilepsy Behav. 27 2013 118 120
92. S. Jozwiak, K. Kotulska, D. Domanska-Pakiela, B. Lojszczyk, M. Syczewska, D. Chmielewski, D. Dunin-Wasowicz, T. Kmiec, J. Szymkiewicz-Dangel, M. Kornacka, W. Kawalec, D. Kuczynski, J. Borkowska, K. Tomaszek, E. Jurkiewicz, and M. Respondek-Liberska Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex Eur. J. Paediatr. Neurol. 15 2011 424 431
93. R. Bombardieri, M. Pinci, R. Moavero, C. Cerminara, and P. Curatolo Early control of seizures improves long-term outcome in children with tuberous sclerosis complex Eur. J. Paediatr. Neurol. 14 2010 146 149
94. E. Ben-Menachem Mechanism of action of vigabatrin: correcting misperceptions Acta Neurol. Scand. Suppl. 2011 5 15
95. B. Zhang, S.S. McDaniel, N.R. Rensing, and M. Wong Vigabatrin inhibits seizures and mtor pathway activation in a mouse model of tuberous sclerosis complex PLoS One 8 2013 e57445
96. S.A. Backman, V. Stambolic, A. Suzuki, J. Haight, A. Elia, J. Pretorius, M.S. Tsao, P. Shannon, B. Bolon, G.O. Ivy, and T.W. Mak Deletion of pten in mouse brain causes seizures, ataxia and defects in soma size resembling lhermitte-duclos disease Nat. Genet. 29 2001 396 403
97. R. Spreafico, and I. Blumcke Focal cortical dysplasias: clinical implication of neuropathological classification systems Acta Neuropathol. 120 2010 359 367
98. S. Fauser, C. Essang, D.M. Altenmuller, A.M. Staack, B.J. Steinhoff, K. Strobl, T. Bast, S. Schubert-Bast, U. Stephani, G. Wiegand, M. Prinz, A. Brandt, J. Zentner, and A. Schulze-Bonhage Long-term seizure outcome in 211 patients with focal cortical dysplasia Epilepsia 56 2015 66 76
99. J.S. Lim, W.I. Kim, H.C. Kang, S.H. Kim, A.H. Park, E.K. Park, Y.W. Cho, S. Kim, H.M. Kim, J.A. Kim, J. Kim, H. Rhee, S.G. Kang, H.D. Kim, D. Kim, D.S. Kim, and J.H. Lee Brain somatic mutations in mtor cause focal cortical dysplasia type ii leading to intractable epilepsy Nat. Med. 2015
100. J.Y. Lee, A.K. Park, E.S. Lee, W.Y. Park, S.H. Park, J.W. Choi, J.H. Phi, K.C. Wang, and S.K. Kim Mirna expression analysis in cortical dysplasia: regulation of mtor and lis1 pathway Epilepsy Res. 108 2014 433 441
101. C.H. Kwon, X. Zhu, J. Zhang, and S.J. Baker Mtor is required for hypertrophy of pten-deficient neuronal soma in vivo Proc. Natl. Acad. Sci. U. S. A. 100 2003 12923 12928
102. M.C. Ljungberg, C.N. Sunnen, J.N. Lugo, A.E. Anderson, and G. D'Arcangelo Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia Dis. Model Mech. 2 2009 389 398
103. L.H. Nguyen, A.L. Brewster, M.E. Clark, A. Regnier-Golanov, C.N. Sunnen, V.V. Patil, G. D'Arcangelo, and A.E. Anderson Mtor inhibition suppresses established epilepsy in a mouse model of cortical dysplasia Epilepsia 56 2015 636 646
104. C.N. Sunnen, A.L. Brewster, J.N. Lugo, F. Vanegas, E. Turcios, S. Mukhi, D. Parghi, G. D'Arcangelo, and A.E. Anderson Inhibition of the mammalian target of rapamycin blocks epilepsy progression in ns-pten conditional knockout mice Epilepsia 52 2011 2065 2075
105. J. Zhou, J. Blundell, S. Ogawa, C.H. Kwon, W. Zhang, C. Sinton, C.M. Powell, and L.F. Parada Pharmacological inhibition of mtorc1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific pten knock-out mice J. Neurosci. 29 2009 1773 1783
106. T.P. Sutula, and F.E. Dudek Unmasking recurrent excitation generated by mossy fiber sprouting in the epileptic dentate gyrus: an emergent property of a complex system Prog. Brain Res. 163 2007 541 563
107. P.S. Buckmaster, E.A. Ingram, and X. Wen Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy J. Neurosci. 29 2009 8259 8269
108. X. Huang, H. Zhang, J. Yang, J. Wu, J. McMahon, Y. Lin, Z. Cao, M. Gruenthal, and Y. Huang Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy Neurobiol. Dis. 40 2010 193 199
109. P.S. Buckmaster, and X. Wen Rapamycin suppresses axon sprouting by somatostatin interneurons in a mouse model of temporal lobe epilepsy Epilepsia 52 2011 2057 2064
110. K. Heng, M.M. Haney, and P.S. Buckmaster High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy Epilepsia 54 2013 1535 1541
111. M. Macias, M. Blazejczyk, P. Kazmierska, B. Caban, A. Skalecka, B. Tarkowski, A. Rodo, J. Konopacki, and J. Jaworski Spatiotemporal characterization of mtor kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment PLoS One 8 2013 e64455
112. L.H. Zeng, N.R. Rensing, and M. Wong Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mtor) pathway Mol. Cell. Pharmacol. 1 2009 124 129
113. M.S. Hester, B.E. Hosford, V.R. Santos, S.P. Singh, I. Rolle, C.L. LaSarge, J.P. Liska, N. Garcia-Cairasco, and S.C. Danzer Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain Exp. Neurol. 2016
114. H. Tang, H. Long, C. Zeng, Y. Li, F. Bi, J. Wang, H. Qian, and B. Xiao Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy Biochem. Biophys. Res. Commun. 420 2012 199 204
115. T. Chachua, K.L. Poon, M.S. Yum, L. Nesheiwat, K. DeSantis, J. Veliskova, and L. Velisek Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide y expression in rats Epilepsia 53 2012 2015 2025
116. L. Asnaghi, P. Bruno, M. Priulla, and A. Nicolin Mtor: a protein kinase switching between life and death Pharmacol. Res. 50 2004 545 549
117. L.H. Zeng, S. McDaniel, N.R. Rensing, and M. Wong Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mtor): a double-edged sword? Cell Cycle 9 2010 2281 2285
118. E.A. van Vliet, G. Forte, L. Holtman, J.C. den Burger, A. Sinjewel, H.E. de Vries, E. Aronica, and J.A. Gorter Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation Epilepsia 53 2012 1254 1263
119. E.A. van Vliet, W.M. Otte, W.J. Wadman, E. Aronica, G. Kooij, H.E. de Vries, R.M. Dijkhuizen, and J.A. Gorter Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats i: magnetic resonance imaging Epilepsia 2015
120. E.A. van Vliet, W.M. Otte, W.J. Wadman, E. Aronica, G. Kooij, H.E. de Vries, R.M. Dijkhuizen, and J.A. Gorter Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats ii: potential mechanisms Epilepsia 2015
121. X. Wang, L. Sha, N. Sun, Y. Shen, and Q. Xu Deletion of mtor in reactive astrocytes suppresses chronic seizures in a mouse model of temporal lobe epilepsy Mol. Neurobiol. 2016
122. E. Russo, R. Citraro, G. Donato, C. Camastra, R. Iuliano, S. Cuzzocrea, A. Constanti, and G. De Sarro Mtor inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy Neuropharmacology 69 2013 25 36
123. A. Coppola, and S.L. Moshe Animal models Handbook Clin. Neurol. 107 2012 63 98
124. R. Citraro, A. Leo, P. De Fazio, G. De Sarro, and E. Russo Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the wag/rij rat model of absence epilepsy Br. J. Pharmacol. 172 2015 3177 3188
125. E. Russo, R. Citraro, F. Scicchitano, A. Urzino, R. Marra, V. Rispoli, and G. De Sarro Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity Behav. Brain Res. 225 2011 373 376
126. E. Russo, P. Follesa, R. Citraro, C. Camastra, A. Donato, D. Isola, A. Constanti, G. De Sarro, and G. Donato The mtor signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model Neurol. Sci. 35 2014 1793 1799
127. E. Russo, F. Andreozzi, R. Iuliano, V. Dattilo, T. Procopio, G. Fiume, S. Mimmi, N. Perrotti, R. Citraro, G. Sesti, A. Constanti, and G. De Sarro Early molecular and behavioral response to lipopolysaccharide in the wag/rij rat model of absence epilepsy and depressive-like behavior, involves interplay between ampk, akt/mtor pathways and neuroinflammatory cytokine release Brain Behav. Immun. 2014
128. D.M. Talos, H. Sun, X. Zhou, E.C. Fitzgerald, M.C. Jackson, P.M. Klein, V.J. Lan, A. Joseph, and F.E. Jensen The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mtor) pathway PLoS One 7 2012 e35885
129. T. Chachua, M.S. Yum, J. Veliskova, and L. Velisek Validation of the rat model of cryptogenic infantile spasms Epilepsia 52 2011 1666 1677
130. A. Pitkanen, T. Bolkvadze, and R. Immonen Anti-epileptogenesis in rodent post-traumatic epilepsy models Neurosci. Lett. 497 2011 163 171
131. A.S. Don, C.K. Tsang, T.M. Kazdoba, G. D'Arcangelo, W. Young, and X.F. Zheng Targeting mtor as a novel therapeutic strategy for traumatic cns injuries Drug Discov. Today 17 2012 861 868
132. X. Zhu, J. Park, J. Golinski, J. Qiu, J. Khuman, C.C. Lee, E.H. Lo, A. Degterev, and M.J. Whalen Role of akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice J. Cereb. Blood Flow Metab. 34 2014 1531 1539
133. J. Park, J. Zhang, J. Qiu, X. Zhu, A. Degterev, E.H. Lo, and M.J. Whalen Combination therapy targeting akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice J. Cereb. Blood Flow Metab. 32 2012 330 340
134. D. Guo, L. Zeng, D.L. Brody, and M. Wong Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury PLoS One 8 2013 e64078
135. M.C. Ljungberg, M.B. Bhattacharjee, Y. Lu, D.L. Armstrong, D. Yoshor, J.W. Swann, M. Sheldon, and G. D'Arcangelo Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia Ann. Neurol. 60 2006 420 429
136. Y. Berdichevsky, A.M. Dryer, Y. Saponjian, M.M. Mahoney, C.A. Pimentel, C.A. Lucini, M. Usenovic, and K.J. Staley Pi3k-akt signaling activates mtor-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy J. Neurosci. 33 2013 9056 9067
137. A.L. Hartman, P. Santos, A. Dolce, and J.M. Hardwick The mtor inhibitor rapamycin has limited acute anticonvulsant effects in mice PLoS One 7 2012 e45156
138. E. Ferlazzo, C. Sueri, S. Gasparini, and U. Aguglia Challenges in the pharmacological management of epilepsy and its causes in the elderly Pharmacol. Res. 2016
139. L. Santulli, A. Coppola, S. Balestrini, and S. Striano The challenges of treating epilepsy with 25 antiepileptic drugs Pharmacol. Res. 2016
140. T.T. Gipson, H. Jennett, L. Wachtel, M. Gregory, A. Poretti, and M.V. Johnston Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior Epilepsy Behav. Case Rep. 1 2013 122 125
141. D.A. Krueger, A.A. Wilfong, K. Holland-Bouley, A.E. Anderson, K. Agricola, C. Tudor, M. Mays, C.M. Lopez, M.O. Kim, and D.N. Franz Everolimus treatment of refractory epilepsy in tuberous sclerosis complex Ann. Neurol. 74 2013 679 687
142. K. Kotulska, D. Chmielewski, J. Borkowska, E. Jurkiewicz, D. Kuczynski, T. Kmiec, B. Lojszczyk, D. Dunin-Wasowicz, and S. Jozwiak Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex Eur. J. Paediatr. Neurol. 17 2013 479 485
143. G. Wiegand, T.W. May, P. Ostertag, R. Boor, U. Stephani, and D.N. Franz Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur. J. Paediatr. Neurol. 17 2013 631 638
144. J. Muncy, I.J. Butler, and M.K. Koenig Rapamycin reduces seizure frequency in tuberous sclerosis complex J. Child Neurol. 24 2009 477
145. M.P. Curran Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex Paediatr. Drugs 14 2012 51 60
146. M. Cardamone, D. Flanagan, D. Mowat, S.E. Kennedy, M. Chopra, and J.A. Lawson Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex J. Pediatr. 164 2014 1195 1200
147. A. Wiemer-Kruel, H. Woerle, K. Strobl, and T. Bast Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report Neuropediatrics 45 2014 129 131
148. D. Domanska-Pakiela, M. Kaczorowska, E. Jurkiewicz, K. Kotulska, D. Dunin-Wasowicz, and S. Jozwiak Eeg abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients Eur. J. Paediatr. Neurol. 18 2014 458 468
149. J.W. Wheless Use of the mtor inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy Epilepsy Behav. Case Rep. 4 2015 63 66
150. A.S. Allen, S.F. Berkovic, P. Cossette, N. Delanty, D. Dlugos, E.E. Eichler, M.P. Epstein, T. Glauser, D.B. Goldstein, Y. Han, E.L. Heinzen, Y. Hitomi, K.B. Howell, M.R. Johnson, R. Kuzniecky, D.H. Lowenstein, Y.F. Lu, M.R. Madou, A.G. Marson, H.C. Mefford, S. Esmaeeli Nieh, T.J. O'Brien, R. Ottman, S. Petrovski, A. Poduri, E.K. Ruzzo, I.E. Scheffer, E.H. Sherr, C.J. Yuskaitis, B. Abou-Khalil, B.K. Alldredge, J.F. Bautista, A. Boro, G.D. Cascino, D. Consalvo, P. Crumrine, O. Devinsky, M. Fiol, N.B. Fountain, J. French, D. Friedman, E.B. Geller, S. Glynn, S.R. Haut, J. Hayward, S.L. Helmers, S. Joshi, A. Kanner, H.E. Kirsch, R.C. Knowlton, E.H. Kossoff, R. Kuperman, S.M. McGuire, P.V. Motika, E.J. Novotny, J.M. Paolicchi, J.M. Parent, K. Park, R.A. Shellhaas, J.J. Shih, R. Singh, J. Sirven, M.C. Smith, J. Sullivan, L. Lin Thio, A. Venkat, E.P. Vining, G.K. Von Allmen, J.L. Weisenberg, P. Widdess-Walsh, and M.R. Winawer De novo mutations in epileptic encephalopathies Nature 501 2013 217 221
151. J.H. Lee, M. Huynh, J.L. Silhavy, S. Kim, T. Dixon-Salazar, A. Heiberg, E. Scott, V. Bafna, K.J. Hill, A. Collazo, V. Funari, C. Russ, S.B. Gabriel, G.W. Mathern, and J.G. Gleeson De novo somatic mutations in components of the pi3k-akt3-mtor pathway cause hemimegalencephaly Nat. Genet. 44 2012 941 945